Advances in Dementia Research Book

	White matter changes: the clinical consequences in the aging population	1
	Longitudinal change of white matter abnormalities	9
	Genetic aspects of microangiopathy-related cerebral damage	15
	Research criteria for subcortical vascular dementia in clinical trials	23
	How can cerebral infarcts and hemorrhages lead to dementia?	31
	Vascular aspects in Alzheimer's disease	37
	Novel imaging technologies in the assessment of cerebral ageing and vascular dementia	45
	Alzheimer disease and neuroinflammation	53
	The immunological microenvironment in the CNS: implications on neuronal cell death and survival	59
	Toxic effector molecules in the pathogenesis of immune-mediated disorders of the central nervous system	69
	Cytokines in CNS disorders: neurotoxicity versus neuroprotection	81
	Do neuronal inclusions kill the cell?	91
	Mechanisms of cell death in neurodegenerative disorders	95
	Estrogens, apoptosis and cells of neural origin	115
	Markers of apoptosis and models of programmed cell death in Alzheimer's disease	125
	Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease	133
	Genetics of Alzheimer's diseases - routes to the pathophysiology	155
	Secretion of the amyloid precursor protein is elevated isoform specifically by apolipoprotein E4	163
	Alterations in neurotrophins and neurotrophin receptors in Alzheimer's disease	171
	Genetically altered transgenic models of Alzheimer's disease	175
	Morphological substrates of mental dysfunction in Lewy body disease: an update	185
	Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach	213
	Understanding the role of estrogen on cognition and dementia	223
	Present and future of Alzheimer therapy	231
	Trials to slow progression and prevent disease onset	243
	Epidemiologic clues to the causes and routes to prevention of Alzheimer disease	251
	Post-transcription modulation of the blood-brain barrier GLUT1 glucose transporter by brain-derived factors	255
	A brain derived peptide preparation reduces the translation dependent loss of a cytoskeletal protein in primary cultured chicken neurons	263
	Neurotrophic effects of Cerebrolysin in animal models of excitotoxicity	273
	Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection	281
	Clinical experience with Cerebrolysin	293
	Approach towards an integrative drug treatment of Alzheimer's disease	301
	Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects	315
	Subject Index	319